Scancell Holdings Plc (SCNLF)
OTC PINK OTC PINK Primary Summary
SCNLF Chart
Melanoma trial success moves Scancell to phase III - ICYMI
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L'Huillier talked with Proactive about new clinical data from its phase two melanoma study, known as the SCOPE trial, featuring its lead ImmunoBody candidate, iSCIB1+. L'Huillier highlighted that the trial has achieved the objectives set out for it, confirming the parameters for the company's upcoming registrational phase three study.
Is Scancell nearing 'significant value crystallisation point'?
There's been an odd reaction to some encouraging news from Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), with the shares barely flickering this week. The company updated the market with more supportive data from a trial of its drug for people with hard-to-treat melanoma, a common skin cancer.
Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript
Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript
Scancell Holdings Plc (SCNLF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Scancell Holdings Plc ever had a stock split?
Scancell Holdings Plc Profile
| Biotechnology Industry | Healthcare Sector | Dr. Phillip John L'Huillier MBA, Ph.D. CEO | OTC PINK Exchange | GB00B63D3314 ISIN |
| GB Country | 61 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Scancell Holdings plc is a trailblazing biopharmaceutical entity immersed in the clinical stage, pioneering in the innovative domain of immunotherapies and vaccines aimed at the confrontation of cancer and infectious diseases. Founded in 1997 and rooted in Oxford, United Kingdom, the company leverages cutting-edge scientific research to develop groundbreaking treatments. Through its dedication to advancing immunotherapy, Scancell Holdings plc embodies a beacon of hope in transforming cancer treatment paradigms and combating emerging infectious threats.
Products and Services
-
SCIB1
An ImmunoBody cancer vaccine currently progressing through Phase II clinical trials, SCIB1 targets the treatment of metastatic melanoma. This pioneering approach harnesses the body's immune system to recognize and combat cancer cells, representing a novel stride within oncologic therapeutics.
-
SCIB2/iSCIB2
In the evaluation phase for patients with solid tumors, including non-small cell lung cancer, SCIB2/iSCIB2 vaccine embodies a groundbreaking immunotherapy angle. It aims to unlock the potential of the immune system in recognizing and destructing tumors, underscoring Scancell's dedication to expanding the frontier of cancer treatment.
-
Modi-1
A vaccine comprising citrullinated peptides, Modi-1 is currently undergoing phase I/II clinical trials for the treatment of various solid tumors including triple negative breast, ovarian, renal, and head and neck cancers. This innovative modality illustrates the company's pursuit of targeting cancer through unique antigenic determinants, offering a glimpse into the future of personalized cancer vaccines.
-
Modi-2
Targeting homocitrullinated cancer antigens, Modi-2 represents another facet of Scancell's strategy in exploiting distinctive cancer characteristics for therapeutic gain. Through this approach, the company endeavors to broaden its impact on cancer care, bringing novel treatment options to patients with dire needs.
-
SCOV1 and SCOV2 COVIDITY
As part of its portfolio expansion into infectious diseases, Scancell is developing a DNA vaccine against the SARS-CoV-2 virus. SCOV1 and SCOV2 COVIDITY venture into the realm of pandemic response, reflecting Scancell's adaptive strategy in leveraging its immunotherapy expertise to address global health emergencies.
